I’m Eyeing 2 Biopharma Stocks Amid Choppy Market Action
These small-cap biotechs offer core businesses that fund a much bigger opportunity.
These small-cap biotechs offer core businesses that fund a much bigger opportunity.
Trump means it … this time … on Iran; U.S. manufacturing churns higher, and Palantir? Wow!
I’ve got two biopharma stocks on my radar ahead of earnings.
While the technical damage is significant in places, the selling is driven by CapEx concerns, not deteriorating fundamentals.
Rising rates and capex fears hit at the same time, but the rotation is limiting the damage.
Dislocations driven by market conditions rather than fundamentals are creating my shopping list.
Trump’s defense of data centers helps the market bounce back from an ugly morning.
We locked in gains on three holdings, giving our cash levels a boost as the Q2 earnings season heats up.
The semiconductor sector is under pressure again Tuesday morning following Samsung Electronics’ earnings news.
The action looked good ahead of the July 4 holiday but then a major shift took semiconductors to the downside.